Migraine Drugs Market Size, Share & Trends Report

Migraine Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Triptans, CGRP-based Therapies, Ditans, Neurotoxins, NSAIDs), By Treatment, By Route Of Administration, And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-2-68038-559-5
  • Number of Pages: 98
  • Format: Electronic (PDF)

Table of Contents

Chapter 1 Report Scope
                   1.1 Treatment Scope
                   1.2 Therapeutic Class Scope
                   1.3 Mode of Administration Scope
                   1.4 Country Scope
                   1.5 Estimates and Forecast Timeline
Chapter 2 Methodology
                   2.1 Research Methodology
                       2.1.1 Information procurement
                   2.2 Information or Data Analysis
                   2.3 Market Formulation & Validation
                   2.4 List of Sources
                   2.5 List of Abbreviations
Chapter 3 Executive Summary
Chapter 4 Disease Primer and Epidemiology
                   4.1 Disease Primer
                       4.1.1 Stages and symptoms
                       4.1.2 Types
                           4.1.2.1 Episodic migraine
                           4.1.2.2 Chronic migraine
                           4.1.2.3 Migraine with Aura
                           4.1.2.4 Migraine without Aura
                           4.1.2.5 Other Forms
                       4.1.3 Causes
                       4.1.4 Risk Factors
                       4.1.5 TRIGGERS
                   4.2 Epidemiology
                       4.2.1 Epidemiological Forecast FOR MIGRAINE FOR Seven Major Markets (U.S., Japan, EU5)
Chapter 5 Global Migraine Market Overview
                   5.1 Introduction and Market Overview
                       5.1.1 Acute treatment
                           5.1.1.1 Triptans
                           5.1.1.2 Ergot Alkaloids
                           5.1.1.3 Non-specific drugs
                       5.1.2 Preventive/ Prophylactic treatment
                   5.2 Market, by Treatment
                   5.3 Market, by Therapeutic Class
                   5.4 Market Size and Forecast by Country (2017 - 2025)
                       5.4.1 Sales Performance by geographic markets, in $ million, 2017 - 2025
                       5.4.2 U.S.
                       5.4.3 Japan
                       5.4.4 U.K.
                       5.4.5 Germany
                       5.4.6 France
                       5.4.7 Spain
                       5.4.8 Italy
                   5.5 Market Share Distribution, by Company (2017 - 2025)
                       5.5.1 Acute Migraine treatment, share distribution by company
                       5.5.2 Preventive Migraine treatment, share distribution by company
                   5.6 Market Dynamics and Brand Strategies
                   5.7 Patent Expiry Schedule
                   5.8 Migraine Drugs Market: Drivers and Restraints
                       5.8.1 Market Drivers and trends
                       5.8.2 Market Restraints
                   5.9 M&A, Deal Landscape (2014-2018 YTD)
                       5.9.1 Mergers & Acquisitions
                       5.9.2 Deals landscape
                   5.10 Emerging Markets
                   5.11 Pricing & Reimbursement
                   5.12 SWOT
Chapter 6 Migraine Drugs Market: Pipeline Intelligence
                   6.1 Pipeline Landscape
                       6.1.1 Leading Drugs in Development
                   6.2 Key R&D Trends
                       6.2.1 Calcitonin gene-related peptide (cgrp) targeting therapies
                           6.2.1.1 cgrp monoclonal antibodies
                           6.2.1.2 CGRP small molecule antagonists: Gepants
                       6.2.2 serotonin -5ht1f receptor agonists: ditans
                       6.2.3 others
                   6.3 Pipeline Landscape
                       6.3.1 late-stage pipeline analysis
                   6.4 Clinical Profiles of Disruptive Drugs
                       6.4.1 Epitinezumab (Alder biopharma)
                       6.4.2 Rimegepant (biohaven)
                       6.4.3 AMG-301 (Amgen)
                       6.4.4 GLObal pipeline forecast
Chapter 7 Company Profiles
                   7.1 Allergan
                       7.1.1 Company Overview
                       7.1.2 Current Product Portfolio
                       7.1.3 Product Forecast Sales up to 2025
                       7.1.4 Strategic Initiatives
                           7.1.4.1 Key Company News Flow
                       7.1.5 Pipeline analysis and overview
                           7.1.5.1 Catalysts & events Calendar
                       7.1.6 SWOT
                   7.2 Amgen
                       7.2.1 Company Overview
                       7.2.2 Current Product Portfolio-
                       7.2.3 Product Forecast Sales up to 2025
                       7.2.4 Strategic Initiatives
                           7.2.4.1 Key Company News Flow
                       7.2.5 Pipeline analysis and overview
                           7.2.5.1 Catalysts & events Calendar
                       7.2.6 SWOT
                   7.3 Teva Pharma
                       7.3.1 Company Overview
                       7.3.2 Current Product Portfolio-
                       7.3.3 Product Forecast Sales up to 2025
                       7.3.4 Strategic Initiatives
                           7.3.4.1 Key Company News Flow
                           7.4.4.2 Catalysts & events Calendar7.3.5 SWOT
                   7.4 GlaxoSmithKline
                       7.4.1 Company Overview
                       7.4.2 Current Product Portfolio-
                       7.4.3 Product Forecast Sales up to 2025
                       7.4.4 Strategic Initiatives
                           7.4.4.1 Key Company News Flow
                       7.4.5 SWOT
                   7.5 Eli Lilly
                       7.5.1 Company Overview
                       7.5.2 Current Product Portfolio
                       7.5.3 Product Forecast Sales up to 2025
                       7.5.4 Strategic Initiatives
                           7.5.4.1 Key Company News Flow
                           7.5.4.2 Catalysts & events Calendar
                       7.5.5 SWOT
                   7.6 Pfizer
                       7.6.1 Company Overview
                       7.6.2 Current Product Portfolio-
                       7.6.3 Product Forecast Sales up to 2025
                       7.6.4 Strategic Initiatives
                           7.6.4.1 Key Company News Flow
                       7.6.5 SWOT
Chapter 8 Market Outlook
                   8.1 Winners and Losers
                       8.1.1 Winners
                       8.1.2 Losers
                   8.2 Emerging Companies/ New Technology Platforms
                       8.2.1 Alder biopharma
                       8.2.2 Biohaven Pharma
                       8.2.3 AOBiome therapeutics
                       8.2.4 Allodynic therapeutics
                       8.2.5 zosano pharma
                   8.3 What the Future Holds


List of Tables

Table 1 List of Abbreviation
Table 2 Forecast Migraine Prevalence, 2017 - 2025
Table 3 Triptans for Acute Migraine Treatment
Table 4 Ergot Alkaloids, NSAIDs, and others for Acute Migraine Treatment
Table 5 First-line, Second-line, and Third-line Therapies for Migraine Prevention
Table 6 Sales by Treatment, in $ Million, 2017 - 2025
Table 7 Sales Performance by Geographic Markets, in $ Million
Table 8 Migraine Drugs Patent Expiry Schedule
Table 9 Annual Cost Associated with Migraine Treatment, by Country ($ Billion)
Table 10 Pricing of Currently Available Therapies for Migraine
Table 11 Migraine R&D Pipeline - by Phase
Table 12 R&D Pipeline Overview
Table 13 Late-stage Pipeline Analysis
Table 14 Epitinezumab
Table 15 Rimegepant
Table 16 AMG-301
Table 17 Pipeline Forecast
Table 18 Product Profile: Botox (onabotulinumtoxinA)
Table 19 Allergan Product Forecast Sales (2017 - 2025)
Table 20 Allergan Pipeline Analysis and Overview
Table 21 Allergan - Catalysts & Events Calendar
Table 22 Product Profile: Aimovig (erenumab)
Table 23 Amgen Product Forecast Sales (2017 - 2025)
Table 24 Amgen Pipeline Analysis and Overview
Table 25 Amgen - Catalysts & Events Calendar
Table 26 Product Profile: Relpax/ Relpert
Table 27 Pfizer Product Forecast Sales (2017 - 2025)
Table 28 Product Profile: Treximet (Sumatriptan + Naproxen Sodium)
Table 29 Product Profile: Amerge (naratriptan)
Table 30 Product Profile: Imitrex (sumatriptan succinate)
Table 31 Efficacy Comparison - Treximet Vs. Imitrex
Table 32 GlaxoSmithKline Product Forecast Sales (2017 - 2025)
Table 33 Product Profile: Emgality (galcanezumab)
Table 34 Emgality Phase III EVOLVE-I and EVOLVE-II Study
Table 35 Emgality Phase III REGAIN Study
Table 36 Product Profile: Lasmiditan
Table 37 Emgality - Phase III SAMURAI Study
Table 38 Emgality - Phase III SPARTAN Study
Table 39 Eli Lilly Product Forecast Sales (2017 - 2025)
Table 40 Eli Lilly-Catalysts & Events Calendar
Table 41 Product Profile: Ajovy (fremanezumab)
Table 42 Ajovy - Phase III HALO (Chronic Migraine) CM Study
Table 43 Ajovy - Phase III HALO (Episodic Migraine) EM Study
Table 44 Teva Product Forecast Sales (2017 - 2025)
Table 45 Teva - Catalysts & Events Calendar


List of Figures

Fig.1 Stages and Symptoms of Migraine
Fig.2 Migraine Types
Fig.3 U.S. - Age and Gender-Specific Migraine Prevalence
Fig.4 Japan - Age and Gender-Specific Migraine Prevalence
Fig.5 U.K. - Age and Gender-Specific Migraine Prevalence
Fig.6 Germany - Age and Gender-Specific Migraine Prevalence
Fig.7 Spain - Age and Gender-Specific Migraine Prevalence
Fig.8 Italy - Age-Specific Migraine Prevalence
Fig.9 Global Migraine Market Share, by Treatment (2017 - 2025)
Fig.10 Market Segmentation and Scope
Fig.11 Migraine Market Share, by Therapeutic Class (2017 - 2025)
Fig.12 Migraine Market Share, by Country (2017 & 2025)
Fig.13 U.S. Migraine Drugs Market, $ Million (2017 - 2025)
Fig.14 Japan Migraine Drugs Treatment Market, $ Million (2017 - 2025)
Fig.15 U.K. Migraine Drugs Market, $ Million (2017 - 2025)
Fig.16 Germany Migraine Drugs Market, $ Million (2017 - 2025)
Fig.17 France Migraine Drugs Market, $ Million (2017 - 2025)
Fig.18 Spain Migraine Drugs Market, $ Million (2017 - 2025)
Fig.19 Italy Migraine Drugs Market, $ Million (2017 - 2025)
Fig.20 Acute Migraine Market Shares Distribution, by Company (2017 & 2025)
Fig.21 Migraine Prevention Market Shares Distribution, by Company (2017 & 2025)
Fig.22 Migraine Drugs Market Sector SWOT
Fig.23 Migraine R&D Pipeline
Fig.24 Migraine R&D Pipeline, by Therapeutic Class
Fig.25 Allergan Migraine Sales Forecast
Fig.26 Allergan SWOT
Fig.27 Aimovig Migraine Sales Forecast
Fig.28 Amgen SWOT
Fig.29 Teva Migraine Sales Forecast
Fig.30 Teva SWOT
Fig.31 Pfizer Migraine Sales Forecast
Fig.32 Pfizer SWOT
Fig.33 GlaxoSmithKline Migraine Sales Forecast
Fig.34 GlaxoSmithKline SWOT
Fig.35 Eli Lilly Migraine Sales Forecast
Fig.36 Eli Lilly SWOT

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.